Psychopharmacology

, Volume 187, Issue 3, pp 268–283 | Cite as

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

  • R. R. Griffiths
  • W. A. Richards
  • U. McCann
  • R. Jesse
Original Investigation

Abstract

Rationale

Although psilocybin has been used for centuries for religious purposes, little is known scientifically about its acute and persisting effects.

Objectives

This double-blind study evaluated the acute and longer-term psychological effects of a high dose of psilocybin relative to a comparison compound administered under comfortable, supportive conditions.

Materials and methods

The participants were hallucinogen-naïve adults reporting regular participation in religious or spiritual activities. Two or three sessions were conducted at 2-month intervals. Thirty volunteers received orally administered psilocybin (30 mg/70 kg) and methylphenidate hydrochloride (40 mg/70 kg) in counterbalanced order. To obscure the study design, six additional volunteers received methylphenidate in the first two sessions and unblinded psilocybin in a third session. The 8-h sessions were conducted individually. Volunteers were encouraged to close their eyes and direct their attention inward. Study monitors rated volunteers’ behavior during sessions. Volunteers completed questionnaires assessing drug effects and mystical experience immediately after and 2 months after sessions. Community observers rated changes in the volunteer’s attitudes and behavior.

Results

Psilocybin produced a range of acute perceptual changes, subjective experiences, and labile moods including anxiety. Psilocybin also increased measures of mystical experience. At 2 months, the volunteers rated the psilocybin experience as having substantial personal meaning and spiritual significance and attributed to the experience sustained positive changes in attitudes and behavior consistent with changes rated by community observers.

Conclusions

When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences. The ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.

Keywords

Psilocybin Methylphenidate Hallucinogen Entheogen Mystical experience Spiritual Religion Anxiety Humans 

Supplementary material

213_2006_457_MOESM1_ESM.doc (6 kb)
Supplementary Table 1States of Consciousness Questionnaire and Pahnke–Richards Mystical Experience Questionnaire (DOC 5 kb)
213_2006_457_MOESM2_ESM.doc (5 kb)
Supplementary Table 2Items in the Persisting Effects Questionnaire used to assess eight categories of possible change in attitudes, mood, social effects, and behavior: I, positive attitudes about life and/or self (17 items); II, negative attitudes about life and/or self (17 items); III, positive mood changes (four items); IV, negative mood changes (four items); V, altruistic/positive social effects (eight items); VI, antisocial/negative social effects (eight items); VII, positive behavior changes (one item); and VIII, negative behavior changes (one item). Numerals associated with each item indicate the numerical sequence of the items. (DOC 5 kb)

References

  1. Abraham HD, Aldridge AM, Gogia P (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14:285–298PubMedCrossRefGoogle Scholar
  2. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX (2005) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30:1154–1162PubMedCrossRefGoogle Scholar
  3. Chait LD (1994) Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 5:281–288PubMedCrossRefGoogle Scholar
  4. Costa PT, McCrae RR (1992) Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Psychological Assessment Resources, Odessa, FLGoogle Scholar
  5. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80–84PubMedCrossRefGoogle Scholar
  6. Dobkin de Rios M, Janiger O (2003) LSD spirituality and the creative process. Park Street, Rochester, VTGoogle Scholar
  7. Doblin R (1991) Pahnke’s Good Friday experiment: a long-term follow-up and methodological critique. J Transpers Psychol 23:1–28Google Scholar
  8. Fantegrossi WE, Woods JH, Winger G (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15:149–157PubMedCrossRefGoogle Scholar
  9. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41–50CrossRefGoogle Scholar
  10. Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse, vol 1. JAI, Greenwich, pp 1–90Google Scholar
  11. Haertzen CA (1966) Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep 18:163–194PubMedGoogle Scholar
  12. Halpern JH, Pope HG (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53:247–256PubMedCrossRefGoogle Scholar
  13. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology (Berl) 172:145–156CrossRefGoogle Scholar
  14. Hollister LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130:42–52PubMedGoogle Scholar
  15. Hood RW Jr, Morris RJ, Watson PJ (1990) Quasi-experimental elicitation of the differential report of mystical experience among intrinsic indiscriminatively pro-religious types. J Sci Study Relig 29:164–172CrossRefGoogle Scholar
  16. Hood RW Jr, Ghorbani N, Watson PJ, Ghramaleki AF, Bing MN, Davison HK, Morris RJ, Williamson WP (2001) Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Study Relig 40:691–705CrossRefGoogle Scholar
  17. Isbell H (1959) Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1:29–38PubMedCrossRefGoogle Scholar
  18. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction. Springer, Berlin Heidelberg New York, pp 197–258Google Scholar
  19. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367–374PubMedCrossRefGoogle Scholar
  20. Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573PubMedCrossRefGoogle Scholar
  21. Leuner H (1981) Halluzinogene psychische grenzzustande in forschung und psychotherapie. Hans Huber, BernGoogle Scholar
  22. Malitz S, Esecover H, Wilkens B, Hoch PH (1960) Some observations on psilocybin, a new hallucinogen, in volunteer subjects. Compr Psychiatry 1:8–17PubMedCrossRefGoogle Scholar
  23. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258PubMedGoogle Scholar
  24. Masters REL, Houston J (1966) The varieties of psychedelic experience. Holt Rinehart & Winston, New YorkGoogle Scholar
  25. Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano, CAGoogle Scholar
  26. Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39Google Scholar
  27. National Institute on Drug Abuse (2001) Hallucinogens and dissociative drugs. National Institute on Drug Abuse research report series, NIH publication, volume 01-4209Google Scholar
  28. National Institute on Drug Abuse (2005) LSD NIDA infofacts. National Institute on Drug Abuse, Rockville, MD, February 2005Google Scholar
  29. Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Ph.D. thesis, Harvard UniversityGoogle Scholar
  30. Pahnke WN (1967) LSD and religious experience. In: DeBold RC, Leaf RC (eds) LSD man & society. Wesleyan University Press, Middletown, CT, pp 60–85Google Scholar
  31. Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149–162PubMedGoogle Scholar
  32. Piedmont RL (1999) Does spirituality represent the sixth factor of personality? Spiritual transcendence and the five-factor model. J Person 67:985–1013CrossRefGoogle Scholar
  33. Piedmont RL (2005) Aspires assessment of spirituality and religious sentiments. Technical Manual, Loyola College in Maryland, Columbia, MDGoogle Scholar
  34. Piedmont RL (2006) Cross-cultural generalizability of the Spiritual Transcendence Scale to the Philippines: spirituality as a universal. Ment Health Relig Cult (In press)Google Scholar
  35. Piedmont RL, Leach MM (2002) Cross-cultural generalizability of the spiritual transcendence scale in India. Am Behav Sci 45:1886–1899CrossRefGoogle Scholar
  36. Presti DE, Nichols DE (2004) Biochemistry and neuropharmacology of psilocybin mushrooms. In: Metzner R, Darling DC (eds) Teonanacatl. Four Trees, El Verano, CA, pp 89–108Google Scholar
  37. Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215–223PubMedCrossRefGoogle Scholar
  38. Richards WA (1975) Counseling, peak experiences and the human encounter with death: an empirical study of the efficacy of DPT-assisted counseling in enhancing the quality of life of persons with terminal cancer and their closest family members. Ph.D. thesis, Catholic University of America, Washington, DCGoogle Scholar
  39. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1–10Google Scholar
  40. Rinkel M, Atwell CR, Dimascio A, Brown J (1960) Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. N Engl J Med 262:295–297PubMedCrossRefGoogle Scholar
  41. Roberts TB (2001) Psychoactive sacramentals: essays on entheogens and religion. Council on Spiritual Practices, San Francisco, CAGoogle Scholar
  42. Rosenberg DE, Isbell H, Miner EJ, Logan CR (1964) The effect of N, N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 5:217–227PubMedCrossRefGoogle Scholar
  43. Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 6:32–44PubMedCrossRefGoogle Scholar
  44. Smith H (1964) Do drugs have religious import? J Philos 61:517–530CrossRefGoogle Scholar
  45. Smith H (2000) Cleansing the doors of perception: the religious significance of entheogenic plants and chemicals. Tarcher/Putnam, New YorkGoogle Scholar
  46. Spilka B, Hood RW, Hunsberger B, Gorsuch R (2005) The psychology of religion: an empirical approach, 3rd edn. Guilford, New YorkGoogle Scholar
  47. Stace WT (1960) Mysticism and philosophy. Lippincott, PhiladelphiaGoogle Scholar
  48. Stamets P (1996) Psilocybin mushrooms of the world: an identification guide. Ten Speed, Berkeley, CAGoogle Scholar
  49. Stolaroff MJ (2001) A protocol for a sacramental service. In: Roberts TB (ed) Psychoactive sacramentals: essays on entheogens and religion. Council on Spiritual Practices, San Francisco, CAGoogle Scholar
  50. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose–response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108PubMedGoogle Scholar
  51. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7–14Google Scholar
  52. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897–3902PubMedCrossRefGoogle Scholar
  53. Wasson RG (1980) The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill, New YorkGoogle Scholar
  54. Watson D, Clark LA (1994) The PANAS-X manual for the positive and negative affect schedule—expanded form. The University of Iowa, Iowa City, IowaGoogle Scholar
  55. Watson D, Clark LA (1997) Measurement and mismeasurement of mood: recurrent and emergent issues. J Pers Assess 68:267–296PubMedCrossRefGoogle Scholar
  56. Wolbach AB Jr, Miner EJ, Isbell H (1962) Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 3:219–223PubMedCrossRefGoogle Scholar
  57. Wulff DM (1991) Psychology of religion; classic and contemporary views. Wiley, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • R. R. Griffiths
    • 1
    • 2
  • W. A. Richards
    • 3
    • 4
  • U. McCann
    • 1
  • R. Jesse
    • 4
  1. 1.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of NeuroscienceJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Johns Hopkins Bayview Medical CenterBaltimoreUSA
  4. 4.Council on Spiritual PracticesSan FranciscoUSA

Personalised recommendations